MARIETTA, Ga., May 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it will attend the 14th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashman, EVP, Chief Commercialization Officer, and Mark Landy, VP, Strategic Initiatives, are scheduled to participate in one-on-one and small group meetings on Wednesday, May 31, 2017, at The Depot Renaissance Minneapolis Hotel.
About MiMedx MiMedx® is a biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 800,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.
Advertisement
About MiMedx MiMedx® is a biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 800,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-to-attend-the-14th-annual-craig-hallum-institutional-investor-conference-300460211.html
SOURCE MiMedx Group, Inc.
